Finzati - Logo
PMCB logo

PharmaCyte Biotech, Inc.

PMCB • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jul 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$4.10M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 45.28Weak profitability
Financial data as of: Jul 31, 2026, 12:00 AM UTCLast earnings update: Jul 31, 2026, 12:00 AM UTCLast profile update: Sep 16, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$4.10M
52W Range0.33 - 1.51
Beta0.66
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio45.28
Quick Ratio45.28
Volume1.03M

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 45.28Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 1/2/2013
Industry: Biotechnology
P/B i: 0.00
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.00
Current Ratio: 45.28
Quick Ratio: 45.28
Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected
WEINSTEIN ROBERT
Transaction: 03/31/2026
BUY
Change
0
Price
Not reported
Filing
07/17/2026
Type
BUY
SCHECHTER JONATHAN
Transaction: 03/31/2026
BUY
Change
0
Price
Not reported
Filing
07/17/2026
Type
BUY
Abecassis Michael M
Transaction: 03/31/2026
BUY
Change
0
Price
Not reported
Filing
07/17/2026
Type
BUY